What is the price of ADMS stock?
One share of ADMS stock can currently be purchased for approximately $8.22. How much money does Adamas Pharmaceuticals make? Adamas Pharmaceuticals has a market capitalization of $376.37 million and generates $74.46 million in revenue each year.
Is Adamas pharmaceuticals (ADM) stock a buy or sell?
Adamas Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 6 hold ratings, and no sell ratings. According to analysts' consensus price target of $7.90, Adamas Pharmaceuticals has a forecasted downside of 3.9% from its current price of $8.22.
What are analysts'price targets for Adamas pharmaceuticals (AMAs)?
Their forecasts range from $6.00 to $9.10. On average, they expect Adamas Pharmaceuticals' stock price to reach $7.90 in the next twelve months. This suggests that the stock has a possible downside of 3.9%. View analysts' price targets for Adamas Pharmaceuticals or view top-rated stocks among Wall Street analysts.
What happened to ADMS?
ROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS).
Is Admp stock a buy?
Adamis Pharmaceuticals Corp (NASDAQ:ADMP) The 1 analysts offering 12-month price forecasts for Adamis Pharmaceuticals Corp have a median target of 1.50, with a high estimate of 1.50 and a low estimate of 1.50. The median estimate represents a +191.32% increase from the last price of 0.51.
Why is Adamis Pharmaceuticals stock dropping?
ADMP are crashing, down over 50% in morning trading after news broke that the Food and Drug Administration (FDA) sent the company a Complete Response Letter (CRL) about its New Drug Application of Epinephrine Injection USP 1:1000, 0.3mg Pre-Filled Single Dose Syringe (Epinephrine Pre-Filled Syringe).
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy.
Headlines
How Much Of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Do Institutions Own?
Adamas Pharmaceuticals (NASDAQ:ADMS) Frequently Asked Questions
6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last year. There are currently 6 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Adamas Pharmaceuticals stock.
Component Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
The Trend in the Analyst Price Target
Over the past 33 weeks, ADMS's average price target has gone down $2.84.
ADMS Broker Recommendations Summary
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
ADMS Target Price
ADMS price target in 14 days: 8.335 USD* upside and 8.209 USD* downside. (Highest and lowest possible predicted price in a 14 day period)
Adamas Pharmaceuticals Inc ( ADMS ) Stock Market info
Recommendations: Buy or sell Adamas Pharmaceuticals stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Adamas Pharmaceuticals share forecasts, stock quote and buy / sell signals below.
Also on walletinvestor.com
Term Box: Best Adamas Pharmaceuticals Inc forecast, ADMS stock price prediction, ADMS forecast, Adamas Pharmaceuticals Inc finance tips, ADMS prediction, Adamas Pharmaceuticals Inc analyst report, ADMS stock price predictions 2022, Adamas Pharmaceuticals Inc stock forecast, ADMS forecast tomorrow, Adamas Pharmaceuticals Inc technical analysis, ADMS stock future price, Adamas Pharmaceuticals Inc projections, Adamas Pharmaceuticals Inc market prognosis, ADMS expected stock price..
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
